<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[endpoint Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/endpoint.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to endpoint]]></description>
	<s:counts start="0" returned="20" found="41" />
	<language>en-us</language>
	<item>
		<title><![CDATA[AVANIR Pharmaceuticals F2Q09 (Qtr End 3/31/09) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-299986.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions. Keith Katkin Thank you, operator. While we're waiting for any questions, I'd like to let everyone know that we'll be presenting at the Deutsche Bank 34th annual healthcare conference on May 19. The live presentation will be webcast and available for replay on our website...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 07 May 2009 12:25:31 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/randall.html"><![CDATA[Randall]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[Endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/avanir+pharmaceuticals.html"><![CDATA[Avanir Pharmaceuticals]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AVNR</category>
		<category domain="tickers">AVNR</category>
	</item>
	<item>
		<title><![CDATA[Xoma Ltd. Q4 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-277913.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator (Operator's instruction) Your first question comes from the line of Joe Pantginis - Merriman Curhan Ford. Joseph Pantginis - Merriman Curhan Ford Congratulations on the progress and looking for the timely fixing of the going concern here. Couple of quick questions in 052; first, is it...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Wed, 11 Mar 2009 18:55:34 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/diabetes.html"><![CDATA[Diabetes]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[Endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/xoma.html"><![CDATA[Xoma]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">XOMA</category>
		<category domain="tickers">XOMA</category>
	</item>
	<item>
		<title><![CDATA[Learn how to control endpoints in this 3 minute video]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=941113]]></link>
		<description><![CDATA[Security has evolved. It's no longer just about having anti-virus software and a firewall. Discover what critical steps and components you may be missing and how Symantec's Altiris endpoint management solutions can provide complete endpoint control and accelerate IT productivity and efficiency. View a product tour and download more detailed...]]></description>
		<s:doctype><![CDATA[Presentations]]></s:doctype>
		<pubDate>Sun, 01 Mar 2009 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/symantec+corp..html"><![CDATA[Symantec Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/antivirus.html"><![CDATA[Antivirus]]></category>
		<category domain="http://resources.bnet.com/topic/video.html"><![CDATA[Video]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[Endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[Security]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SYMC</category>
		<category domain="tickers">SYMC</category>
	</item>
	<item>
		<title><![CDATA[Amicus Therapeutics, Inc. Q3 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-251157.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Operator instructions We&#8217;ll take our first question from Matt Osborne with Lazard. Matt Osborne &#8211; Lazard Hi, guys. Thanks for taking the question. I have a few questions, if I could start with Matt perhaps. Have you reached an agreement with either of the agencies in...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 20 Nov 2008 09:30:29 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/update.html"><![CDATA[Update]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[Endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/emea.html"><![CDATA[EMEA]]></category>
		<category domain="http://resources.bnet.com/topic/amicus+therapeutics+inc..html"><![CDATA[Amicus Therapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">FOLD</category>
		<category domain="tickers">FOLD</category>
	</item>
	<item>
		<title><![CDATA[i2Telecom Receives Notice of Allowance from U.S. Patent and Trademark Office for "Dynamic Transmission of Packets Over Broadband" Patent]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_14/ai_n30891523]]></link>
		<description><![CDATA[Patent Covers Technology Utilized by OEMs and Communication Services Providers; Company Believes Patent Substantially Exceeds Value of VoiceStick([R]) Patent Previously Sold for $6.5 Million  ATLANTA -- i2Telecom International, Inc. ("i2Telecom([R])") (OTCBB: ITUI), a leading developer of award-winning patented and innovative high-quality mobile applications products and services, today announced that...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 14 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/allowance.html"><![CDATA[Allowance]]></category>
		<category domain="http://resources.bnet.com/topic/bandwidth.html"><![CDATA[bandwidth]]></category>
		<category domain="http://resources.bnet.com/topic/broadband.html"><![CDATA[broadband]]></category>
		<category domain="http://resources.bnet.com/topic/codec.html"><![CDATA[codec]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+patent+and+trademark+office.html"><![CDATA[U.S. Patent and Trademark Office]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[etrials Worldwide to Report Second Quarter 2008 Financial Results]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_August_1/ai_n27966007]]></link>
		<description><![CDATA[MORRISVILLE, N.C. -- etrials([R]) Worldwide, Inc. (Nasdaq: ETWC), a leading provider of adaptive eClinical software and services that optimize clinical trial management by turning data into intelligence and shortening the pathway to an actionable study endpoint will release financial results for the three months ended June 30, 2008 on Tuesday,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 01 Aug 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/financial.html"><![CDATA[financial]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[MARKETING]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/web.html"><![CDATA[Web]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Improved Technology and Unified Communications Create a Case for Videoconferencing Infrastructure]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_20/ai_n25435582]]></link>
		<description><![CDATA[PALO ALTO, Calif. -- From siloed solutions, conferencing is rapidly evolving to be included along with technologies such as data, collaboration, secure instant messaging, unified messaging, and VoIP to form a complete solution. The emergence of total unified communications UC is transforming videoconferencing's long-standing status as a niche technology for...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 20 May 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/collaboration.html"><![CDATA[Collaboration]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/frost+%2526+sullivan.html"><![CDATA[Frost & Sullivan]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[etrials Worldwide to Report First Quarter 2008 Financial Results]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_5/ai_n25382877]]></link>
		<description><![CDATA[MORRISVILLE, N.C. -- etrials([R]) Worldwide, Inc. (Nasdaq: ETWC), a leading provider of adaptive eClinical software and services that optimize clinical trial management by turning data into intelligence and shortening the pathway to an actionable study endpoint, today announced that it will release financial results for the three months ended March...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 05 May 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/financial.html"><![CDATA[financial]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/web.html"><![CDATA[Web]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Inspire to Discontinue Development of Epinastine Nasal Spray]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_23/ai_n25342473]]></link>
		<description><![CDATA[DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that its Phase 3 trial with epinastine nasal spray for the treatment of seasonal allergic rhinitis SAR did not meet its primary endpoint.  "Our analysis of the overall data in this program and the current competitive environment in allergic...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 23 Apr 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/inspire+pharmaceuticals+inc..html"><![CDATA[Inspire Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISPH</category>
		<category domain="tickers">ISPH</category>
	</item>
	<item>
		<title><![CDATA[Research and Markets: World Network Access Control Technologies Markets Report Views NAC as a Solution Framework That Enables Organizations to Protect the Endpoint]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_11/ai_n25148879]]></link>
		<description><![CDATA[DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c88442) announces the addition of new Frost & Sullivan report "World Network Access Control Technologies Markets" to their offering.  Frost & Sullivan does not view NAC as a market of point devices or licenses that are sold and easily counted. Instead Frost &...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 11 Apr 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/frost+%2526+sullivan.html"><![CDATA[Frost & Sullivan]]></category>
		<category domain="http://resources.bnet.com/topic/network.html"><![CDATA[network]]></category>
		<category domain="http://resources.bnet.com/topic/networking.html"><![CDATA[NETWORKING]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[AVANT's Single-Dose Oral Ty800 Vaccine Meets Primary Endpoints in Phase 2 Study]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_1/ai_n24965656]]></link>
		<description><![CDATA[NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today that the double-blind, placebo-controlled multi-center Phase 2 clinical trial of its typhoid fever vaccine candidate, Ty800, met all primary endpoints. The Phase 2 study was an out-patient, dose-ranging clinical trial in 183 healthy volunteers that evaluated two dose levels of...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 01 Apr 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_March_24/ai_n24945726]]></link>
		<description><![CDATA[TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that its Phase 3 clinical trial evaluating the Company's exclusively-licensed technology from the Mayo Clinic consisting of an intranasal antifungal lavage, SinuNase[TM] (topical amphotericin B 0.01% suspension) achieved, as anticipated, superior resolution of the cardinal symptoms of chronic sinusitis CS, as...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 24 Mar 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biovest+international+inc..html"><![CDATA[Biovest International Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/inflammation.html"><![CDATA[inflammation]]></category>
		<category domain="http://resources.bnet.com/topic/mayo+clinic.html"><![CDATA[Mayo Clinic]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
		<category domain="tickers">BVTI</category>
	</item>
	<item>
		<title><![CDATA[etrials Worldwide to Report Fourth Quarter and Full Year 2007 Financial Results]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Feb_21/ai_n24318444]]></link>
		<description><![CDATA[MORRISVILLE, N.C. -- etrials([R]) Worldwide, Inc. (Nasdaq: ETWC), a leading provider of adaptive eClinical software and services that optimize clinical trial management by turning data into intelligence and shortening the pathway to an actionable study endpoint, today announced that it will release financial results for the three months and fiscal...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 21 Feb 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/financial.html"><![CDATA[financial]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/web.html"><![CDATA[Web]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Bradford Networks Collaborates with Aruba Networks to Develop Aruba Endpoint Compliance System]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_August_24/ai_n27354836]]></link>
		<description><![CDATA[Extends Aruba's NAC capabilities with advanced identity, endpoint, and policy tools]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 24 Aug 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/aruba+networks.html"><![CDATA[Aruba Networks]]></category>
		<category domain="http://resources.bnet.com/topic/compliance.html"><![CDATA[compliance]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARUN</category>
		<category domain="tickers">ARUN</category>
	</item>
	<item>
		<title><![CDATA[Future Bulls ADMD, AVNR and EPCT.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200705/ai_n19724914]]></link>
		<description><![CDATA[M2 PRESSWIRE-3 May 2007-AheadoftheBulls.com: Future Bulls ADMD,  AVNR and EPCTC1994-2007 M2 COMMUNICATIONS LTD    RDATE:03052007    New York-AheadoftheBulls.com, announces the following companies as  high potential, Future Bulls: Advanced Medical Iso (Pink Sheets: ADMD),  Avanir Pharmaceuticals (NASDAQ GM: AVNR) and EpiCept Corporation (NASDAQ ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 03 May 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avanir+pharmaceuticals.html"><![CDATA[Avanir Pharmaceuticals]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/epicept+corp..html"><![CDATA[EpiCept Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[therapy]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AVNR</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">EPCT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">AVNR,EPCT,NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Nabi Biopharmaceuticals Announces Results of Phase IIb Trial of NicVAX.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200705/ai_n19722285]]></link>
		<description><![CDATA[M2 PRESSWIRE-2 May 2007-Making The Watchlist: Nabi  Biopharmaceuticals Announces Results of Phase IIb Trial of  NicVAXC1994-2007 M2 COMMUNICATIONS LTD    RDATE:02052007    Market Gainer is quickly emerging as the one stop shop for  international small-cap investors looking to stay a step ahead of...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 02 May 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cigarette.html"><![CDATA[cigarette]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/investor.html"><![CDATA[investor]]></category>
		<category domain="http://resources.bnet.com/topic/nabi+biopharmaceuticals.html"><![CDATA[Nabi Biopharmaceuticals]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NABI</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NABI,NDAQ</category>
	</item>
	<item>
		<title><![CDATA[ARIAD Provides Update Regarding AP23573 Phase 3 Trial in Metastatic Sarcoma]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_April_5/ai_n27194946]]></link>
		<description><![CDATA[CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that the Company has received feedback from the U.S. Food and Drug Administration FDA regarding its Special Protocol Assessment on the design and endpoints for its Phase 3 pivotal trial of oral AP23573, its novel mTOR inhibitor, in metastatic sarcoma....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 05 Apr 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Barrier Therapeutics Announces Positive Results From Azoline Study.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200703/ai_n20187272]]></link>
		<description><![CDATA[M2 PRESSWIRE-27 March 2007-Top Of Our Radar: Barrier Therapeutics  Announces Positive Results From Azoline StudyC1994-2007 M2  COMMUNICATIONS LTD    RDATE:27032007    Market Gainer is quickly emerging as the one stop shop for  international small-cap investors looking to stay a step ahead of the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 27 Mar 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/barrier.html"><![CDATA[barrier]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/infection.html"><![CDATA[infection]]></category>
		<category domain="http://resources.bnet.com/topic/investor.html"><![CDATA[investor]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[SECURITY]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Great Bay Software Is Reed Smith's Vendor of Choice for Global Deployment of Endpoint Profiling]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200702/ai_n18621604]]></link>
		<description><![CDATA[Great Bay Software, Inc., an innovator of 802.1X-enabled Endpoint Profiling security solutions for enterprise networks, has been selected as the vendor of choice to enable the global deployment and securing of the authenticated-enabled network at Reed Smith LLP, one of the 15 largest law firms in the world. Great Bay,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 20 Feb 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/network.html"><![CDATA[network]]></category>
		<category domain="http://resources.bnet.com/topic/reed+smith.html"><![CDATA[Reed Smith]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Immunicon Achieves Endpoint in its Pivotal Clinical Trial in Metastatic Androgen-Independent Prostate Cancer]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Jan_18/ai_n27116846]]></link>
		<description><![CDATA[HUNTINGDON VALLEY, Pa. -- Immunicon Corporation (NASDAQ-GM:IMMC) announced today that the Company met its primary endpoint associated with its pivotal clinical trial in metastatic androgen-independent prostate cancer. The primary endpoint was that circulating tumor cells CTC levels three-to-five weeks after the initiation of chemotherapy would predict overall survival. The study...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 18 Jan 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[clinical trial]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
